Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals Holding Corp a clinicalstage biopharmaceutical company focuses on discovering acquiring developing and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering Its portfolio includes immunology rare disease infectious disease and central nervous system CNS product candidates The companys immunology portfolio includes biologics to address organ transplant rejection autoimmunity and cancer including TNX1500 a humanized monoclonal antibody targeting CD40ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases Its rare disease portfolio comprises TNX2900 for the treatment of PraderWilli syndrome The companys infectious disease pipeline includes TNX801 a vaccine to prevent smallpox and monkeypox TNX1840 and TNX1850 that are live virus vaccines based on its recombinant pox vaccine RPV platform for COVID19 TNX3500 a small molecule antiviral drug to treat acute COVID19 and TNX102 SL a small molecule drug to treat Long COVID a chronic postacute COVID19 condition Its CNS portfolio includes small molecules and biologics to treat pain neurologic psychiatric and addiction conditions including TNX102 SL which is in midPhase 3 development for the management of fibromyalgia TNX1900 that is in development for the prevention of migraine headache and TNX1300 a biologic designed to treat cocaine intoxication The company was founded in 2007 and is headquartered in Chatham New Jersey